| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.2 | 0.2 | 0.0 |
| Other income | 0.1 | 0.0 | 0.3 |
| Total income | 1.2 | 0.2 | 0.3 |
| Profit before exceptional items & tax | 0.6 | -0.3 | 0.2 |
| Profit before tax | 0.6 | -0.3 | 0.2 |
| Net profit | 0.5 | -0.3 | 0.2 |
| Operating margin | 50.0% | -150.0% | 66.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +150.00% |
|---|
Source
Read the filing ↗
BSE results filing, BSE: 534920. Figures extracted from the filing.
Covidh Technologies Ltd: key numbers
- Share price
- ₹143.90
- Market cap
- ₹121.0 Cr
- Revenue (annual)
- ₹1.36 Cr
- Net profit (annual)
- ₹0.26 Cr
- P/E (TTM)
- 466.5×Sector 22.1×
- Promoter holding
- 58.63%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Covidh Technologies Ltd
All →
19:30 IST
BSE
Annual Report
iSERA Lifesciences Annual Report
iSERA Lifesciences Limited has submitted its Annual Report for the financial year 2025-26. The 34th Annual General Meeting is scheduled for September 29, 2026.
14:40 IST
BSE
Financial Results
iSERA Lifesciences Q1 FY27 Results: Net Loss of ₹0.3 Cr
iSERA Lifesciences Ltd reported a net loss of ₹0.3 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.3 Cr